Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-266969
Filing Date
2025-11-05
Accepted
2025-11-05 16:15:37
Documents
56
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-20250930.htm   iXBRL 10-Q 1989780
2 EX-31.1 lrmr-ex31_1.htm EX-31.1 11721
3 EX-31.2 lrmr-ex31_2.htm EX-31.2 11835
4 EX-32.1 lrmr-ex32_1.htm EX-32.1 21019
  Complete submission text file 0001193125-25-266969.txt   8501605

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20250930.xsd EX-101.SCH 1042068
59 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20250930_htm.xml XML 1701786
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 251454213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)